Find your next paid study

Phrontline BiopharmaNCT07181473

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN)

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving…

Lung CancerNSCLCNSCLC Stage IV

Jun Zhang, MD, PhDNCT05332925

~$10 – $1,125

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary…

Olema Pharmaceuticals, Inc.NCT06784193

Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), n…

A2 Biotherapeutics Inc.NCT06682793

Observational

Phase 0 Trial of Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA N…

NSCLCNon Small Cell Lung Cancer

University of Texas Southwestern Medical CenterNCT06552000

~$10 – $6,250

Phase 2

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated …

Non Small Cell Lung CancerNSCLCKRAS G12C

Ryan Gentzler, MDNCT06248606

~$10 – $7,500

Phase 2

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therap…

Non Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-small Cell Carcinoma+2 more

Memorial Sloan Kettering Cancer CenterNCT05657873

~$10 – $6,250

Lung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, Adult+2 more

KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumo…

Krystal Biotech, Inc.NCT06228326

Phase 2

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzu…

Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more

Jun Zhang, MD, PhDNCT05859217

~$10 – $7,500

MesotheliomaPancreatic CancerNSCLC (Advanced Non-small Cell Lung Cancer)

A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours

An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

Orion Corporation, Orion PharmaNCT07563738

Non-small Cell Lung Cancer(NSCLC)Head and Neck Squamous Cell Carcinoma(HNSCC)Renal Cell Carcinoma(RCC)+2 more

A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(…

Assessing the Impact of Circadian Rhythm on Anti-PD-1/PD-L1 Immunotherapy

This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Pat…

Advanced/Metastatic NSCLC